Search Result

Results for "

0.29

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) AMPK (1) Apoptosis (6) Autophagy (3) Bacterial (3) Bcl-2 Family (1) Beta-lactamase (1) Biochemical Assay Reagents (1) Btk (1) CDK (1) CFTR (1) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (4) ClpP (1) Dengue virus (1) DNA/RNA Synthesis (1) EGFR (7) Endogenous Metabolite (1) Enterovirus (1) Epigenetic Reader Domain (2) ERK (1) Estrogen Receptor/ERR (2) Flavivirus (1) FLT3 (3) GABA Receptor (2) Glycosidase (1) HCV (1) HCV Protease (1) HDAC (2) HIV Protease (1) IGF-1R (1) IKK (1) Influenza Virus (1) Integrin (2) IRE1 (1) JNK (1) Melanocortin Receptor (2) mGluR (2) Microsomal Triglyceride Transfer Protein (MTP) (1) Microtubule/Tubulin (2) Monoamine Transporter (1) mTOR (1) Na+/K+ ATPase (2) Necroptosis (1) NF-κB (1) NOD-like Receptor (NLR) (1) Parasite (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) Phosphoglycerate Dehydrogenase (PHGDH) (1) PI3K (2) PIKfyve (1) Potassium Channel (1) PPAR (1) Protease Activated Receptor (PAR) (1) Proton Pump (3) SARS-CoV (1) SHP2 (1) Src (1) TAM Receptor (3) TGF-β Receptor (1) Toll-like Receptor (TLR) (1) Trk Receptor (1) TRP Channel (1) Tyrosinase (1) VEGFR (1) YAP (1) γ-secretase (1)
By Research Areas:	Cancer (34) Cardiovascular Disease (4) Endocrinology (1) Infection (10) Inflammation/Immunology (8) Metabolic Disease (8) Neurological Disease (12)

By Targets:

Adenosine Receptor (1)

AMPK (1)

Apoptosis (6)

Autophagy (3)

Bacterial (3)

Bcl-2 Family (1)

Beta-lactamase (1)

Biochemical Assay Reagents (1)

Btk (1)

CDK (1)

CFTR (1)

Checkpoint Kinase (Chk) (1)

Cholinesterase (ChE) (4)

ClpP (1)

Dengue virus (1)

DNA/RNA Synthesis (1)

EGFR (7)

Endogenous Metabolite (1)

Enterovirus (1)

Epigenetic Reader Domain (2)

ERK (1)

Estrogen Receptor/ERR (2)

Flavivirus (1)

FLT3 (3)

GABA Receptor (2)

Glycosidase (1)

HCV (1)

HCV Protease (1)

HDAC (2)

HIV Protease (1)

IGF-1R (1)

IKK (1)

Influenza Virus (1)

Integrin (2)

IRE1 (1)

JNK (1)

Melanocortin Receptor (2)

mGluR (2)

Microsomal Triglyceride Transfer Protein (MTP) (1)

Microtubule/Tubulin (2)

Monoamine Transporter (1)

mTOR (1)

Na+/K+ ATPase (2)

Necroptosis (1)

NF-κB (1)

NOD-like Receptor (NLR) (1)

Parasite (1)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (1)

Phosphoglycerate Dehydrogenase (PHGDH) (1)

PI3K (2)

PIKfyve (1)

Potassium Channel (1)

PPAR (1)

Protease Activated Receptor (PAR) (1)

Proton Pump (3)

SARS-CoV (1)

SHP2 (1)

Src (1)

TAM Receptor (3)

TGF-β Receptor (1)

Toll-like Receptor (TLR) (1)

Trk Receptor (1)

TRP Channel (1)

Tyrosinase (1)

VEGFR (1)

YAP (1)

γ-secretase (1)

By Research Areas:

Cancer (34)

Cardiovascular Disease (4)

Endocrinology (1)

Infection (10)

Inflammation/Immunology (8)

Metabolic Disease (8)

Neurological Disease (12)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160477

DC-SX029	PIKfyve NF-κB IKK	Inflammation/Immunology
DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated K_D constant of ~0.935 μM by surface plasmon resonance (SPR). DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research .

HY-120837

PZ-II-029	GABA Receptor	Neurological Disease
PZ-II-029 is a GABAA positive allosteric modulator that selectively binds with high affinity to α6β3γ2. PZ-II-029 shows anti-migraine effects .

HY-126288

ASTX029 4 Publications Verification	ERK Apoptosis	Cancer
ASTX029 (Example 1) is a potent dual ERK1/2 inhibitor (IC₅₀: 2.7 nM). ASTX029 has anti-cancer activity .

HY-155537

*YK-029A*	EGFR	Cancer
YK-029A is an orally active inhibitor of mutant EGFR，targeting to both the T790M mutations (EGFR ^T790M) and exon 20 insertion of EGFR (EGFRex20ins). YK-029A exhibits significant antitumor activity，and results tumor regression in EGFRex20ins-driven PDX models .

HY-W011246

Velnacrine maleate HP 029; Hydroxytacrine maleate	Cholinesterase (ChE)	Neurological Disease
Velnacrine maleate (HP 029) is an orally active cholinesterase inhibitor that can be used for the research of Alzheimer's disease .

HY-NP029

Human Serum Albumin-RBITC HSA-RBITC	Biochemical Assay Reagents	Others
Human Sermu Albumin-RBITC (HSA-RBITC) is a kind of biological materials or organic compounds that are widely used in life science research .

HY-19229

TAK-029	Integrin	Cardiovascular Disease
TAK-029 is a potent GP IIb/IIIa antagonist. TAK-029 has potent antithrombotic effects with bleeding time (BT) prolongation in arterial thrombosis models. TAK-029 can be used for the research of various arterial thrombotic diseases .

HY-120459

Rs-029	Na+/K+ ATPase	Others
Rs-029 is an inhibitor Na+/K+ ATPase and an activator for Mg2+ ATPase. Rs-029 decreases the ATP level in red blood cells .

HY-128131

*UCCF-029* free base**	Others	Others
UCCF-029 Free base is a potent activator of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel. UCCF-029 Free base exhibits enhanced activity through benzannulation of the flavone A-ring at the 7,8-position. UCCF-029 Free base serves as a structural guide for the development of more effective flavonoid analogues. UCCF-029 Free base demonstrates improved potency compared to apigenin in activating wild-type CFTR. UCCF-029 Free base also exhibits potential for activating the mutant CFTR (G551D-CFTR) though not as robustly as apigenin.

HY-163319

NCA029	ClpP Apoptosis	Cancer
NCA029 is a potent and selective homo sapiens caseinolytic protease P (HsClpP) activator with an EC₅₀ of 0.15 μM. NCA029 acts on HsClpP to activate an ATF3-dependent integrative stress response, leading to colon cancer cell death .

HY-14919A

Denibulin hydrochloride MN-029	Others	Cancer
Denibulin (MN-029) hydrochloride is an anti-angiogenic agent with anticancer activity. It can cause rapid closure of blood vessels in solid tumors and lead to dose-dependent killing of tumor cells, effectively enhancing the antitumor effects of radiation and cisplatin chemotherapy .

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

HY-127165

Velnacrine HP 029 free base; Hydroxytacrine	Cholinesterase (ChE)	Neurological Disease
Velnacrine (HP 029 free base) is an inhibitor for acetylcholinesterase (AChE), with an IC₅₀ of 3.27 μM. Velnacrine reverses the Scopolamine (HY-N0296)-induced amnesia in rat models, and exhibits acute toxicity with LD₅₀ of 65 mg/kg .

HY-148189

Aldometanib 4 Publications Verification LXY-05-029	AMPK	Metabolic Disease
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .

HY-160170

Necrosis inhibitor 3	Necroptosis	Cancer
Necrosis inhibitor 3 (compound B3) is a poteng inhibitor of necrosis, with the IC₅₀ value of 0.29 nM in HT29 cells .

HY-132905

Antileishmanial agent-2	Parasite	Infection
Antileishmanial agent-2 shows submicromolar antileishmanial activity (IC₅₀ = 0.29 μM) and a very high selectivity index with respect to mammalian cells.

HY-12432A

Gilteritinib hemifumarate 30+ Cited Publications ASP2215 hemifumarate	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) hemifumarate is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀ of 0.29 nM/0.73 nM, respectively.

HY-12432

Gilteritinib 30+ Cited Publications ASP2215	FLT3 TAM Receptor	Cancer
Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-N3202

Neolitsine (+)-Neolitsine	Others	Cardiovascular Disease
Neolitsine ((+)-Neolitsine) is a vasodilator. Neolitsine can be isolated from the herb Cassytha filiformis. Neolitsine exhibits significant vasodilatory effects on precontracted rat aortic preparations with an IC₅₀ of 0.29 μM .

HY-120690

RO5464466	Influenza Virus	Infection
RO5464466 is an hemagglutinin (HA) inhibitor of influenza H1N1 viruses. RO5464466 inhibits HA-mediated hemolysis of chicken erythrocytes with the IC₅₀ of 0.29 μM .

HY-141865

Adenosine receptor antagonist 1	Adenosine Receptor	Cancer
Adenosine receptor antagonist 1 is a A2aR-selective antagonist with an IC₅₀ of 0.29 nM and displays 14-fold more selective for A2aR than A2bR.

HY-100763

Mcl1-IN-12	Bcl-2 Family	Cancer
Mcl1-IN-12 (Compound F) is a selective Mcl-1 inhibitor, less potent at Bcl-2, with K_is of 0.29 and 3.1 μM, respectively. Anti-tumor activity .

HY-163664

Tubulin polymerization-IN-63	Microtubule/Tubulin	Cancer
Tubulin polymerization-IN-63 (compound 6) is a tubulin polymerization inhibitor. The IC₅₀ value of Tubulin polymerization-IN-63 for MES-SA cells is 0.29 μM. Tubulin polymerization-IN-63 can be used in cancer research .

HY-P1215

HS024	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-P1215A

HS024 TFA	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-108555

FR-171113	Protease Activated Receptor (PAR)	Cardiovascular Disease
FR171113 is a specific and non-peptide thrombin receptor antagonist. FR171113 exhibits the antithrombotic effects of a PAR1 antagonist. FR171113 inhibits thrombin-induced platelet aggregation with an IC₅₀ of 0.29 μM. .

HY-161443

TEAD-IN-9	YAP	Cancer
TEAD-IN-9 (compound 17) is a TEAD1 inhibitor with an IC₅₀ of 0.29 μM. TEAD-IN-9 targets the palmitoyl pocket of TEAD, thereby effectively inhibiting the binding of YAP-TEAD and blocking the transcriptional function of YAP-TEAD .

HY-137502

ML267	Bacterial	Infection
ML267 a potent Sfp phosphopantetheinyl transferase (PPTases) inhibitor with an IC₅₀ of 0.29 μM. ML267 also inhibits AcpS-PPTase with an IC₅₀ of 8.1 μM. ML267 possesses specific Gram-positive-targeted bactericidal activities .

HY-111772A

(R)-Elexacaftor (R)-VX-445	CFTR	Inflammation/Immunology
(R)-Elexacaftor is an enantiomer of Elexacaftor (HY-111772). (R)-Elexacaftor is the Compound 37 from patent WO2018107100A1. (R)-Elexacaftor is a modulator of cystic fibrosis transmembrane conductance regulator (CFTR), the EC50 for CFTR dF508 is 0.29 uM .

HY-12432R

Gilteritinib (Standard)	FLT3 TAM Receptor	Cancer
Gilteritinib (Standard) is the analytical standard of Gilteritinib. This product is intended for research and analytical applications. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC₅₀s of 0.29 nM/0.73 nM, respectively.

HY-155211

mTOR inhibitor-13	mTOR PI3K	Cancer
mTOR inhibitor-13 (compound 9g), an aryl ureido compound, is a potent and selective mTOR inhibitor with an IC₅₀ of 0.29 nM. mTOR inhibitor-13 also inhibits PI3K-α with an IC₅₀ of 119 nM .

HY-161310

Metallo-β-lactamase-IN-15	Beta-lactamase	Infection
Metallo-β-lactamase-IN-15 (Compound ±13) is a potent MBL inhibitor, the IC₅₀ values for NDM-1、IMP-1 and VIM-2 were 0.29 μM, 0.088 μM and 0.063 μM, respectively .

HY-100781A

L-AP4 L-APB	mGluR	Neurological Disease
L-AP4 (L-APB) is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

HY-100781B

L-AP4 monohydrate L-APB monohydrate	mGluR	Neurological Disease
L-AP4 (L-APB) monohydrate is a potent and specific agonist for the group III mGluRs, with EC₅₀s of 0.13, 0.29, 1.0, 249 μM for mGlu₄, mGlu₈, mGlu₆ and mGlu₇ receptors, respectively .

HY-100246

CI-1044 PD-189659	Phosphodiesterase (PDE)	Inflammation/Immunology
CI-1044 is an orally active PDE4 inhibitor with IC₅₀s of 0.29, 0.08, 0.56, 0.09 μM for PDE4A5, PDE4B2, PDE4C2 and PDE4D3, respectively.

HY-107600

IQ-3 2 Publications Verification	JNK	Inflammation/Immunology
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively .

HY-13636

Fulvestrant Maximum Cited Publications 86 Publications Verification ICI 182780; ZD 9238; ZM 182780	Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-143293

VEGFR-IN-3	VEGFR Apoptosis	Cancer
VEGFR-IN-3 (compound 3f) is a VEGFR inhibitor. VEGFR-IN-3 inhibits OVCAR-4 and MDA-MB-468 cancer cells growth with IC₅₀s of 0.29 and 0.35 μM, respectively. VEGFR-IN-3 can be used for the research of cancer .

HY-159489

SDUY038	SHP2	Cancer
SDUY038 is a SHP2 allosteric inhibitor, with an IC₅₀ of 1.2 μM and K_D of 0.29 μM, respectively. SDUY038 exhibits pan-antitumor activity (IC₅₀ = 7-24 μM) by suppressing pERK expression. SDUY038 exhibits t_1/2 of 3.95 h by oral administration .

HY-161456

PHGDH-IN-5	Phosphoglycerate Dehydrogenase (PHGDH)	Cancer
PHGDH-IN-5 (Compound B12) is a covalen inhibitor of PHGDH with an IC₅₀ value of 0.29 μM. PHGDH-IN-5 can inhibit cell proliferation in cancer cell lines overexpressing PHGDH. PHGDH-IN-5 can reduce the production of serine derived from glucose in MDA-MB-468 cells .

HY-13898

Taselisib 15+ Cited Publications GDC-0032; RG-7604	PI3K	Cancer
Taselisib (GDC-0032) is a potent PI3K inhibitor targets PIK3CA mutations, with K_is of 0.12 nM, 0.29 nM, 0.97 nM, and 9.1 nM for PI3Kδ, PI3Kα, PI3Kγ and PI3Kβ, respectively.

HY-162255

CDK2-IN-23	CDK	Cancer
CDK2-IN-23 (Compound 17) is a kinase selective and highly potent CDK2 inhibitor (IC₅₀ = 0.29 nM). CDK2-IN-23 shows the pharmacodynamic inhibition of CDK2 in CCNE1-amplified mouse models. CDK2-IN-23 can be used for the research of cancer .

HY-159482

SBN-284	Cholinesterase (ChE) NOD-like Receptor (NLR)	Neurological Disease
SBN-284 (compound 3x) is a dual inhibitor of blood-brain permeable Cholinesterases and the NLRP3 inflammasome and is effective against EeAChE, hAChE and eqBChE, the IC₅₀ values of are 0.37, 0.31, 0.29 μM respectively, and the EC₅₀ of NLRP3 inflamm is 1 μM. SBN-284 can be used in Alzheimer's disease research .

HY-12164

Mocetinostat 10+ Cited Publications MGCD0103	HDAC Autophagy Apoptosis	Cancer
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.

HY-13636R

Fulvestrant (Standard) Maximum Cited Publications 86 Publications Verification ICI 182780(Standard); ZD 9238(Standard); ZM 182780 (Standard)	Estrogen Receptor/ERR Autophagy Apoptosis	Cancer
Fulvestrant (Standard) is the analytical standard of Fulvestrant. This product is intended for research and analytical applications. Fulvestrant (ICI 182780) is a pure antiestrogen and a potent estrogen receptor (ER) antagonist with an IC₅₀ of 9.4 nM. Fulvestrant is also a GPR30 agonist. Fulvestrant effectively inhibits the growth of ER-positive MCF-7 cells with an IC₅₀ of 0.29 nM. Fulvestrant also induces autophagy and has antitumor efficacy .

HY-164523

PV1162	Checkpoint Kinase (Chk)	Cancer
PV1162 is a selective Chk2 inhibitor with an IC₅₀ of 0.29 nM. PV1162 inhibits ATP binding to Chk2 by targeting the gatekeeper-dependent hydrophobic pocket, which is specific to Chk2 and located behind the ATP-binding site (adenine-binding region), thereby inhibiting the phosphorylation activity of Chk2. PV1162 holds potential application value in the field of cancer therapy .

HY-W062835A

CGP77675 hydrate	Src	Cancer
CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity .

HY-162715

EV-A71-IN-2	Enterovirus	Infection
EV-A71-IN-2 (compound 6c) is a anti-EV-A71 agent with the EC₅₀ values of 0.29 μM and 1.66 μM aganist of EV-A71-MRC-5 cells and EV-A71-RD cells, respectively. EV-A71-IN-2 can be used for study of enterovirus infection .

HY-133012

GFB-8438	TRP Channel	Neurological Disease
GFB-8438 is a potent and subtype selective TRPC5 inhibitor, with IC₅₀s of 0.18 and 0.29 μM of hTRPC5 and hTRPC4, respectively. GFB-8438 shows excellent selectivity against TRPC6, other TRP family members, NaV 1.5, as well as limited activity against the hERG channel. GFB-8438 protects mouse podocytes from injury induced by protamine sulfate model .

HY-151534

PBRM1-BD2-IN-7	Epigenetic Reader Domain	Cancer
PBRM1-BD2-IN-7 is a selective and cell-active polybromo-1 (PBRM1) bromodomain inhibitor. PBRM1-BD2-IN-7 has inhibitory activity for PBRM1-BD2 with an IC₅₀ value of 0.29 μM. PBRM1-BD2-IN-7 can be used for the research of cancer .

Cat. No.	Product Name

HY-L029

Autophagy Compound Library

1,473 compounds

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, and homeostasis. The process of autophagy in mammalian cells is as follows: a portion of cytoplasm, including organelles, is enclosed by a phagophore or isolation membrane to form an autophagosome. The outer membrane of the autophagosome subsequently fuses with the endosome and then the lysosome, and the internal material is degraded. Autophagy plays a wide variety of physiological and pathophysiological roles. Defective autophagy contributes to various pathologies, including infections, cancer, neurodegeneration, aging, and heart disease.

MCE provides a unique collection of 1,473 autophagy pathway-related compounds that is a useful tool for the research of autophagy-related regulation and diseases.

Cat. No.	Product Name	Type

HY-NP029

Human Serum Albumin-RBITC HSA-RBITC	Native Proteins
Human Sermu Albumin-RBITC (HSA-RBITC) is a kind of biological materials or organic compounds that are widely used in life science research .

Cat. No.	Product Name	Target	Research Area

HY-P1215A

HS024 TFA	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

HY-P1215

HS024	Melanocortin Receptor	Metabolic Disease
HS024 is a selective MC4 receptor antagonist, with K_is of 0.29, 3.29, 5.45, and 18.6 nM for MC4, MC5, MC3, and MC1, respectively. HS024 increase food intake .

Cat. No.	Product Name	Target	Research Area

HY-P99588

Stamulumab MYO-029	TGF-β Receptor	Metabolic Disease
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research .

Species:	Human (3)
Tag:	His (1) GST (1) Fc (1)
Source:	HEK293 (2) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source

HY-P71471

	HADHB Protein, Human (GST) 3-ketoacyl-CoA thiolase; Acetyl CoA acyltransferase; Acetyl-CoA acyltransferase; Beta ketothiolase; Beta-ketothiolase; ECHB; ECHB_HUMAN; HADH; Hadhb; beta subunit; Hydroxyacyl Coenzyme A (CoA) dehydrogenase beta subunit; MGC87480; MSTP 029; MSTP029; MTPB; TP beta; TP-beta; TPbeta; Trifunctional enzyme subunit beta; Trifunct	Human	E. coli
	HADHB protein is an important component of mitochondrial trifunctional enzymes and directs three decisive reactions in the mitochondrial β-oxidation pathway. This pathway is critical for generating energy across tissues, breaking down long-chain fatty acids into acetyl-CoA. HADHB Protein, Human (GST) is the recombinant human-derived HADHB protein, expressed by E. coli , with N-GST labeled tag.

HY-P76117

	TSPAN8 Protein, Human (HEK293, His) Tetraspanin-8; Tspan-8; CO-029; TSPAN8; TM4SF3	Human	HEK293
	TSPAN8 is a cell surface glycoprotein that is complexed with integrins and belongs to the four-span protein family. It has four hydrophobic domains. TSPAN8 mediates extracellular signal transduction processes and regulates cell development, activation, growth, and movement. In addition, TSPAN8 is expressed in different cancers and has potential roles in cancer prognosis and targeted therapy. TSPAN8 Protein, Human (HEK293, His) is the recombinant human-derived TSPAN8 protein, expressed by HEK293 , with N-His, N-6*His labeled tag. The total length of TSPAN8 Protein, Human (HEK293, His) is 96 a.a., with molecular weight of ~17 & 13 kDa, respectively.

HY-P76118

	TSPAN8 Protein, Human (HEK293, Fc) Tetraspanin-8; Tspan-8; CO-029; TSPAN8; TM4SF3	Human	HEK293
	TSPAN8 is a cell surface glycoprotein that is complexed with integrins and belongs to the four-span protein family. It has four hydrophobic domains. TSPAN8 mediates extracellular signal transduction processes and regulates cell development, activation, growth, and movement. In addition, TSPAN8 is expressed in different cancers and has potential roles in cancer prognosis and targeted therapy. TSPAN8 Protein, Human (HEK293, Fc) is the recombinant human-derived TSPAN8 protein, expressed by HEK293 , with N-mFc labeled tag. The total length of TSPAN8 Protein, Human (HEK293, Fc) is 96 a.a., with molecular weight of ~46 kDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P81413

	ARID1A Antibody (YA1158) ARID1A; BAF250; C1orf4; ELD; HOSA1; Osa homolog 1; OSA1 nuclear protein; SMARCF1; MRD14; p270; B120; BM029	IHC-P	Human
	ARID1A Antibody (YA1158) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA1158), targeting ARID1A. ARID1A Antibody (YA1158) can be used for IHC-P experiment in human background.